Showing results (41-50 of 95) with videos related to

Sort By:
Pageof 10
ACR Open Rheumatology|August 18, 2023
Combining Clinical and Biological Data to Predict Progressive Pulmonary Fibrosis in Patients With Systemic Sclerosis Despite Immunomodulatory TherapyElizabeth R Volkmann, Holly Wilhalme, Shervin Assassi, et al.
Toxicology Letters|July 26, 2005
Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinolTheodore Sarafian, Nancy Habib, Jenny T Mao, et al.
Arthritis and Rheumatism|June 10, 2004
Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosisPhilip J Clements, Jonathan G Goldin, Eric C Kleerup, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2004
Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharideJenny T Mao, I-Hsien Tsu, Steven M Dubinett, et al.
Journal of Virology|May 21, 2010
Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteinsKouki Morizono, Amy Ku, Yiming Xie, et al.
The Journal of Infectious Diseases|February 25, 2003
Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaineAngela Hanchi Shay, Ruth Choi, Katherine Whittaker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2003
Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokersJenny T Mao, Michael D Roth, Kenneth J Serio, et al.
Arthritis Care & Research|December 23, 2024
Treatment Response Biomarkers for Systemic Sclerosis-Associated Interstitial Lung DiseaseElizabeth R Volkmann, Holly Wilhalme, Donald P Tashkin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 27, 2021
Systemic Sclerosis-Associated Interstitial Lung Disease: How to Incorporate Two Food and Drug Administration-Approved Therapies in Clinical PracticeDinesh Khanna, Alain Lescoat, David Roofeh, et al.
ACR Open Rheumatology|May 21, 2020
Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study IIElizabeth R Volkmann, Donald P Tashkin, Holly LeClair, et al.
Pageof 10